• Je něco špatně v tomto záznamu ?

Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies

G. Wandeler, E. Mauron, A. Atkinson, JF. Dufour, D. Kraus, P. Reiss, L. Peters, F. Dabis, J. Fehr, E. Bernasconi, M. van der Valk, C. Smit, LK. Gjærde, J. Rockstroh, D. Neau, F. Bonnet, A. Rauch, Swiss HIV Cohort Study, Athena Observational...

. 2019 ; 71 (2) : 274-280. [pub] 20190406

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028862

BACKGROUND & AIMS: Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study. METHODS: We included all HIV-infected adults with a positive hepatitis B surface antigen test followed in 4 prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors. RESULTS: A total of 3,625 HIV/HBV-coinfected patients were included, of whom 72% had started TDF-containing ART. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% CI 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10-year increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was only above the commonly used screening threshold of 2 cases per 1,000 py in patients aged >45 years old at TDF initiation. CONCLUSIONS: Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients without cirrhosis who started TDF aged <46 years old. LAY SUMMARY: We investigated the incidence of hepatocellular carcinoma in HIV/hepatitis B virus-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed hepatocellular carcinoma. The incidence of hepatocellular carcinoma remained low in patients without cirrhosis, who started on tenofovir disoproxil fumarate when aged <46 years old.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028862
003      
CZ-PrNML
005      
20210114155235.0
007      
ta
008      
210105s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jhep.2019.03.032 $2 doi
035    __
$a (PubMed)30965070
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Wandeler, Gilles $u Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Switzerland. Electronic address: gilles.wandeler@insel.ch.
245    10
$a Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies / $c G. Wandeler, E. Mauron, A. Atkinson, JF. Dufour, D. Kraus, P. Reiss, L. Peters, F. Dabis, J. Fehr, E. Bernasconi, M. van der Valk, C. Smit, LK. Gjærde, J. Rockstroh, D. Neau, F. Bonnet, A. Rauch, Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort,
520    9_
$a BACKGROUND & AIMS: Robust data on hepatocellular carcinoma (HCC) incidence among HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large multi-cohort study. METHODS: We included all HIV-infected adults with a positive hepatitis B surface antigen test followed in 4 prospective European cohorts. The primary outcome was the occurrence of HCC. Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis was defined according to results from liver biopsy or non-invasive measurements. Multivariable Poisson regression was used to assess HCC risk factors. RESULTS: A total of 3,625 HIV/HBV-coinfected patients were included, of whom 72% had started TDF-containing ART. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of HCC remained stable over time among individuals on TDF, whereas it increased steadily among those not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% CI 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at initiation of TDF (adjusted incidence rate ratio per 10-year increase: 2.2, 95% CI 1.6-3.0) and the presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the incidence of HCC was only above the commonly used screening threshold of 2 cases per 1,000 py in patients aged >45 years old at TDF initiation. CONCLUSIONS: Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it remained below the HCC screening threshold in patients without cirrhosis who started TDF aged <46 years old. LAY SUMMARY: We investigated the incidence of hepatocellular carcinoma in HIV/hepatitis B virus-coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 individuals (1.7%) developed hepatocellular carcinoma. The incidence of hepatocellular carcinoma remained low in patients without cirrhosis, who started on tenofovir disoproxil fumarate when aged <46 years old.
650    _2
$a oportunní infekce doprovázející AIDS $x farmakoterapie $x virologie $7 D017088
650    _2
$a dospělí $7 D000328
650    _2
$a látky proti HIV $x terapeutické užití $7 D019380
650    _2
$a hepatocelulární karcinom $x epidemiologie $7 D006528
650    _2
$a koinfekce $x farmakoterapie $x virologie $7 D060085
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a HIV $7 D006678
650    _2
$a hepatitida B $x farmakoterapie $x virologie $7 D006509
650    _2
$a hepatitida B - antigeny povrchové $x analýza $7 D006514
650    _2
$a virus hepatitidy B $x imunologie $7 D006515
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a nádory jater $x epidemiologie $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a tenofovir $x terapeutické užití $7 D000068698
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mauron, Etienne $u Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.
700    1_
$a Atkinson, Andrew $u Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.
700    1_
$a Dufour, Jean-François $u University Clinic for Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland.
700    1_
$a Kraus, David $u Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland; Department of Mathematics and Statistics, Masaryk University, Brno, Czech Republic.
700    1_
$a Reiss, Peter $u HIV Monitoring Foundation, Amsterdam, the Netherlands; Department of Global Health, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands; Division of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, the Netherlands.
700    1_
$a Peters, Lars $u CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Dabis, François $u ISPED, Université Bordeaux, Centre INSERM U1219-Epidémiologie Biostatistique, France.
700    1_
$a Fehr, Jan $u Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland; Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
700    1_
$a Bernasconi, Enos $u Division of Infectious Diseases, Regional Hospital Lugano, Switzerland.
700    1_
$a van der Valk, Marc $u Division of Infectious Diseases, Amsterdam University Medical Centers, Location AMC, the Netherlands.
700    1_
$a Smit, Colette $u HIV Monitoring Foundation, Amsterdam, the Netherlands.
700    1_
$a Gjærde, Lars K $u CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
700    1_
$a Rockstroh, Jürgen $u Department of Medicine I, University Hospital Bonn, Bonn, Germany.
700    1_
$a Neau, Didier $u CHU de Bordeaux, Service de Maladies Infectieuses et Tropicales, Bordeaux, France.
700    1_
$a Bonnet, Fabrice $u ISPED, Université Bordeaux, Centre INSERM U1219-Epidémiologie Biostatistique, France; CHU Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Bordeaux, France.
700    1_
$a Rauch, Andri $u Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.
710    2_
$a Swiss HIV Cohort Study, Athena Observational Cohort Study, EuroSIDA, ANRS CO3 Aquitaine Cohort
773    0_
$w MED00010017 $t Journal of hepatology $x 1600-0641 $g Roč. 71, č. 2 (2019), s. 274-280
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30965070 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155233 $b ABA008
999    __
$a ok $b bmc $g 1609197 $s 1120042
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 71 $c 2 $d 274-280 $e 20190406 $i 1600-0641 $m Journal of hepatology $n J Hepatol $x MED00010017
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace